InnoCare Pharma Dirección
Dirección controles de criterios 3/4
El CEO de InnoCare Pharma es Jasmine Cui , nombrado en Aug 2016, tiene una permanencia de 8.25 años. compensación anual total es CN¥22.63M, compuesta por 20.8% salario y 79.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.73% de las acciones de la empresa, por valor de HK$783.44M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 9 años, respectivamente.
Información clave
Jasmine Cui
Chief Executive Officer (CEO)
CN¥22.6m
Compensación total
| Porcentaje del salario del CEO | 20.8% |
| Permanencia del CEO | 8.3yrs |
| Participación del CEO | 5.7% |
| Permanencia media de la dirección | 3.2yrs |
| Promedio de permanencia en la Junta Directiva | 9yrs |
Actualizaciones recientes de la dirección
Recent updates
Is InnoCare Pharma (HKG:9969) A Risky Investment?
Oct 21
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%
Sep 13Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report
Aug 22Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Jun 21Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates
Apr 02Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?
Feb 14Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Oct 06Is InnoCare Pharma (HKG:9969) Using Too Much Debt?
May 11Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?
Apr 11Is InnoCare Pharma (HKG:9969) A Risky Investment?
Jan 25Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Sep 05InnoCare Pharma (HKG:9969) Is Using Debt Safely
Apr 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CN¥376m |
| Jun 30 2024 | n/a | n/a | -CN¥471m |
| Mar 31 2024 | n/a | n/a | -CN¥761m |
| Dec 31 2023 | CN¥23m | CN¥5m | -CN¥631m |
| Sep 30 2023 | n/a | n/a | -CN¥584m |
| Jun 30 2023 | n/a | n/a | -CN¥867m |
| Mar 31 2023 | n/a | n/a | -CN¥781m |
| Dec 31 2022 | CN¥24m | CN¥4m | -CN¥887m |
| Sep 30 2022 | n/a | n/a | -CN¥987m |
| Jun 30 2022 | n/a | n/a | -CN¥296m |
| Mar 31 2022 | n/a | n/a | -CN¥78m |
| Dec 31 2021 | CN¥29m | CN¥3m | -CN¥65m |
| Sep 30 2021 | n/a | n/a | CN¥60m |
| Jun 30 2021 | n/a | n/a | -CN¥266m |
| Mar 31 2021 | n/a | n/a | -CN¥329m |
| Dec 31 2020 | CN¥120m | CN¥1m | -CN¥391m |
| Sep 30 2020 | n/a | n/a | -CN¥2b |
| Jun 30 2020 | n/a | n/a | -CN¥2b |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥17m | CN¥3m | -CN¥2b |
| Sep 30 2019 | n/a | n/a | -CN¥742m |
| Jun 30 2019 | n/a | n/a | -CN¥592m |
| Mar 31 2019 | n/a | n/a | -CN¥571m |
| Dec 31 2018 | CN¥26m | CN¥2m | -CN¥550m |
Compensación vs. Mercado: La compensación total de Jasmine($USD3.12M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD487.93K).
Compensación vs. Ingresos: La compensación de Jasmine ha sido consistente con los resultados de la empresa en el último año.
CEO
Jasmine Cui (61 yo)
8.3yrs
Permanencia
CN¥22,626,000
Compensación
Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 8.3yrs | CN¥22.63m | 5.73% HK$ 783.4m | |
| VP of Clinical Development & Medical Research and Executive Director | no data | CN¥4.06m | 8.21% HK$ 1.1b | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Chief Operating Officer | 3.3yrs | sin datos | sin datos | |
| Accounting Supervisor | no data | sin datos | sin datos | |
| Chief Technology Officer | 5.1yrs | sin datos | 0.0071% HK$ 969.8k | |
| General Counsel | 3.2yrs | sin datos | sin datos | |
| VP & Head of Biology | 3.2yrs | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos | |
| Secretary of the Board | no data | sin datos | sin datos |
3.2yrs
Permanencia media
52.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 9969 se considera experimentado (3.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 9yrs | CN¥22.63m | 5.73% HK$ 783.4m | |
| VP of Clinical Development & Medical Research and Executive Director | 9yrs | CN¥4.06m | 8.21% HK$ 1.1b | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive Director & President of Scientific Advisory Board | 9yrs | sin datos | 0.18% HK$ 24.1m | |
| Member of Scientific Advisory Board | 9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive Director | 3.7yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 4.7yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 1.1yrs | sin datos | sin datos |
9.0yrs
Permanencia media
55.5yo
Promedio de edad
Junta con experiencia: La junta directiva de 9969 se considera experimentada (9 años de antigüedad promedio).